NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

• ClinicalTrials.gov Identifier: NCT04675450
• Recruitment Status: Not yet recruiting
• First Posted: December 19, 2020
• Last Update Posted: October 14, 2022
• Sponsor: Conjupro Biotherapeutics, Inc.
• Collaborator: CSPC-NBP Pharmaceutical Co., Ltd.
• Information provided by (Responsible Party): Conjupro Biotherapeutics, Inc.

Tracking Information

• First Submitted Date: November 20, 2020
• First Posted Date: December 19, 2020
• Last Update Posted Date: October 14, 2022
• Estimated Study Start Date: June 30, 2023
• Estimated Primary Completion Date: December 30, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 14, 2020)

Mean Change from Baseline in EORTC Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Sensory Subscale [ Time Frame: Baseline and weeks 5, 8, 11 and 15 ]

Change from baseline in the mean EORTC QLQ-CIPN20 sensory subscale (converted to a 0-100 scale) collected during the treatment period at weeks 5, 8, 11 and 15.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: December 14, 2020)

• Number of Participants Requiring Rescue Medication [ Time Frame: 15 weeks ]
  The number and percentage of participants requiring oxycodone of any amount anytime during the 15 week treatment period.
• Days Free of Rescue Medication [ Time Frame: 15 weeks ]
  The mean cumulative number of days free of oxycodone of any amount anytime for each participant during the 15 week treatment period.
• Mean Change from Baseline in the Brief Pain Inventory Short Form (mBPI-SF) score. [ Time Frame: 15 weeks ]
  The mean change from baseline (mean days 2-7 after first dose of NBP or Placebo) in the mBPI-SF total score to mean of all post-nab-paclitaxel mBPI-SF scores collected on days 2-7 after each of 4 nab-paclitaxel administration at days 7, 28, 49 and 70 during the 15 week treatment period.
• Number of Participants with Treatment-Emergent Adverse Events [ Time Frame: 19 weeks ]
  The number and percentage of participants with treatment-emergent adverse events according to MedDRA system organ class and preferred term with onset during the 15 week treatment period or 4 week follow-up.
• Area Under the Curve (AUC) for NBP [ Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7 ]
  The AUC (h*ng/mL) be calculated using Phoenix WinNonlin software
• Cmax for NBP [ Time Frame: Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7 ]
  Cmax (ng/mL) be calculated using Phoenix WinNonlin software
• Tmax for NBP [ Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7 ]
  Tmax (hr) be calculated using Phoenix WinNonlin software
• Area Under the Curve for Paclitaxel [ Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7 ]
  AUC (h*ng/mL) be calculated using Phoenix WinNonlin software
• Cmax for Paclitaxel [ Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7 ]
  Cmax (ng/mL) be calculated using Phoenix WinNonlin software
• Tmax for Paclitaxel [ Time Frame: Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7 ]
  Tmax (hr) be calculated using Phoenix WinNonlin software

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
• Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of n-Butylphthalide (NBP) Softgel Capsules Administered to Patients With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
• Brief Summary: Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.
• Detailed Description: This is a multiple center, randomized, double-blind, Phase 2 study of NBP administered to women with metastatic breast cancer who receive nab-paclitaxel as therapy. Nab-paclitaxel will be administered at a dose >260 mg/m2 every 3 weeks for 4 planned cycles. Subjects will begin receiving NBP orally at a dose of 400 mg administered every 12-hours (BID) or matching placebo 5 days (10 doses) prior to starting nab-paclitaxel therapy and continue to self-administer it BID until Visit 6/Day 100/Week 15. The primary objective is to evaluate the efficacy of NBP relative to placebo at preventing or reducing symptoms associated with nab-paclitaxel induced toxic neuropathy (CIPN). The secondary objectives include an evaluation the efficacy of NBP relative to placebo at preventing or attenuating taxane induced acute pain syndrome (TAPS), the evaluation of the safety and tolerability of NBP relative to placebo and to determine if NBP administration impacts the pharmacokinetics of nab-paclitaxel or if nab-paclitaxel affects the pharmacokinetics of NBP.
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Prevention

Condition

• Breast Cancer
• Peripheral Neuropathy

Intervention

• Drug: Placebo
  Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
  Other Name: NBP Placebo Softgel Capsules
• Drug: NBP Softgel Capsules
  Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
  Other Name: NBP

Study Arms

• Placebo Comparator: Placebo
  Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
  Intervention: Drug: Placebo
• Active Comparator: NBP
  Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
  Intervention: Drug: NBP Softgel Capsules

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Not yet recruiting
• Estimated Enrollment (submitted: December 14, 2020): 60
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: January 30, 2025
• Estimated Primary Completion Date: December 30, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria

Subjects are eligible to participate in the study only if all the following criteria apply:

1. Women aged ≥18 and ≤75 years.
2. Pathologically confirmed metastatic breast cancer.
3. Are candidates for initial therapy with nab-paclitaxel, at a dose of >260 mg/m2 every 3 weeks for 4 planned cycles.
4. Concomitant antitumor drugs used to treat the underlying malignancy, including immunotherapies, other than nab-paclitaxel will be allowed.
5. Eastern Cooperative Oncology Group (ECOG) performance status scores of 0 - 2.
6. Life expectancy ≥6 months.
7. Women of childbearing potential (WOCBP) must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening and be practicing a medically acceptable method of contraception with an annual failure rate of less than 1% until the completion of the trial or 30 days after discontinuation of study treatment. Women are considered not childbearing if they are >1 year postmenopausal or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation).
8. Able to complete study questionnaires by themselves or with assistance.
9. Capable of understanding the purpose and risks of the study and able to provide informed consent by signing the informed consent form.
10. Able to swallow softgel capsules as determined by the investigator.
11. Able to comply with all study requirements. Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

1. Non-metastatic breast cancer.
2. Subjects who are pregnant, lactating/breast-feeding, or plan to become pregnant within the next 3 months.
3. History of poorly controlled diabetes mellitus (hemoglobin A1C >8.0 at the time of the Screening visit).
4. History of fibromyalgia.
5. History of any signs or symptoms suggestive of neuropathy within 30 days of Screening as determined by the investigator based on the neurological examination.
6. History of taking any neurotoxic drugs within 6 months of Screening.
7. Current use of drugs that are used to treat neuropathic pain (eg, gabapentin, pregabalin, and duloxetine) within 30 days of Screening.
8. Current diagnosis of malignancy other than breast cancer.
9. Absolute neutrophil count <1.5 x 109 cells/L.
10. Platelet count <100,000 x 109/L.
11. Hemoglobin level <9 g/dL at Screening without transfusion (transfusion independent).
12. Corrected QTcF >470 msec (single tracing) at Screening and prior to randomization.
13. Chronic renal or hepatic disease.
14. Clinically significant renal dysfunction including serum creatinine level >1.5 mg/dL or calculated creatinine clearance ≥50 mL/minute at Screening.
15. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level >2.0 x upper limits of normal (ULN), or a bilirubin >1.5 x ULN unless in the setting of known Gilbert's disease at Screening.
16. History of HIV, hepatitis B, hepatitis C, or tuberculosis.
17. Major surgical procedures ≤30 days prior to starting study drug, or minor surgical procedures ≤7 days prior to starting study drug.
18. History of alcohol or drug dependence or is known to have abused alcohol within 30 days prior to screening.
19. Unwilling to abstain from alcohol and recreational drugs (with exception for medical marijuana) throughout the duration of participation in the study.
20. Positive urine drug screen at Screening (with exception for medical marijuana which is allowed).
21. Known hypersensitivity to celery or soybeans.
22. Known serious hypersensitivity to paclitaxel
23. Received treatment with any other investigational drug within 30 days before screening, was previously treated with NBP, is currently taking celery seed extract, or is currently participating in another clinical study
24. Any other reasons that in the opinion of the investigator make the subject unsuitable for enrollment.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Contacts

Contact: Audrey Li; 609-356-0210; clinicaltrials.gov@cspcus.com

• Listed Location Countries: Not Provided

Administrative Information

• NCT Number: NCT04675450
• Other Study ID Numbers: CPO-NBP-2002
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Conjupro Biotherapeutics, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Conjupro Biotherapeutics, Inc.
• Original Study Sponsor: Same as current
• Collaborators: CSPC-NBP Pharmaceutical Co., Ltd.

Investigators

• Study Director: Qingxi Wang, PhD; Conjupro Biotherapeutics, Inc.

• PRS Account: Conjupro Biotherapeutics, Inc.
• Verification Date: October 2022